Cerebral protective effects of etomidate: experimental and clinical aspects.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Reduction of cerebral blood flow below a critical threshold for a protracted time interval results in irreversible metabolic events culminating in cell death. The development of agents capable of extending the tolerable ischemic interval is of great importance as such agents may allow time for therapeutic measures to be accomplished which could restore cerebral perfusion. This issue is of particular pertinence in the treatment of complex cerebrovascular diseases when local (or global) cerebral blood flow must be interrupted during vascular reconstruction. Thiopental achieved great popularity once protective properties were demonstrated experimentally. Unfortunately, serious cardiovascular depression associated with high-dose barbiturates as well as prolonged duration of action may decrease collateral flow and limit their utility. Etomidate is a nonbarbiturate carboxylated imidazole which is capable of similar cerebral metabolic suppression without significant cardiac side effects. Accumulating experimental evidence supports the protective properties of this drug and suggests that it may be valuable clinically for this purpose. Significant adrenal suppression is a major toxic effect that must be treated if large doses or protracted administration is planned.

Original languageEnglish (US)
Pages (from-to)17-32
Number of pages16
JournalCerebrovascular and Brain Metabolism Reviews
Volume5
Issue number1
StatePublished - Mar 1993

Fingerprint

Cerebrovascular Circulation
Etomidate
blood flow
protective effect
cerebrovascular disorders
thiopental
barbiturates
Cerebrovascular Disorders
Protective Agents
Barbiturates
imidazoles
Thiopental
Poisons
dosage
blood vessels
Blood Vessels
cell death
Cell Death
Perfusion
adverse effects

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cerebral protective effects of etomidate : experimental and clinical aspects. / Batjer, H. H.

In: Cerebrovascular and Brain Metabolism Reviews, Vol. 5, No. 1, 03.1993, p. 17-32.

Research output: Contribution to journalArticle

@article{ab4b2d66181b4a558f311d2b20d00207,
title = "Cerebral protective effects of etomidate: experimental and clinical aspects.",
abstract = "Reduction of cerebral blood flow below a critical threshold for a protracted time interval results in irreversible metabolic events culminating in cell death. The development of agents capable of extending the tolerable ischemic interval is of great importance as such agents may allow time for therapeutic measures to be accomplished which could restore cerebral perfusion. This issue is of particular pertinence in the treatment of complex cerebrovascular diseases when local (or global) cerebral blood flow must be interrupted during vascular reconstruction. Thiopental achieved great popularity once protective properties were demonstrated experimentally. Unfortunately, serious cardiovascular depression associated with high-dose barbiturates as well as prolonged duration of action may decrease collateral flow and limit their utility. Etomidate is a nonbarbiturate carboxylated imidazole which is capable of similar cerebral metabolic suppression without significant cardiac side effects. Accumulating experimental evidence supports the protective properties of this drug and suggests that it may be valuable clinically for this purpose. Significant adrenal suppression is a major toxic effect that must be treated if large doses or protracted administration is planned.",
author = "Batjer, {H. H.}",
year = "1993",
month = "3",
language = "English (US)",
volume = "5",
pages = "17--32",
journal = "Cerebrovascular and Brain Metabolism Reviews",
issn = "1040-8827",
publisher = "Raven Press",
number = "1",

}

TY - JOUR

T1 - Cerebral protective effects of etomidate

T2 - experimental and clinical aspects.

AU - Batjer, H. H.

PY - 1993/3

Y1 - 1993/3

N2 - Reduction of cerebral blood flow below a critical threshold for a protracted time interval results in irreversible metabolic events culminating in cell death. The development of agents capable of extending the tolerable ischemic interval is of great importance as such agents may allow time for therapeutic measures to be accomplished which could restore cerebral perfusion. This issue is of particular pertinence in the treatment of complex cerebrovascular diseases when local (or global) cerebral blood flow must be interrupted during vascular reconstruction. Thiopental achieved great popularity once protective properties were demonstrated experimentally. Unfortunately, serious cardiovascular depression associated with high-dose barbiturates as well as prolonged duration of action may decrease collateral flow and limit their utility. Etomidate is a nonbarbiturate carboxylated imidazole which is capable of similar cerebral metabolic suppression without significant cardiac side effects. Accumulating experimental evidence supports the protective properties of this drug and suggests that it may be valuable clinically for this purpose. Significant adrenal suppression is a major toxic effect that must be treated if large doses or protracted administration is planned.

AB - Reduction of cerebral blood flow below a critical threshold for a protracted time interval results in irreversible metabolic events culminating in cell death. The development of agents capable of extending the tolerable ischemic interval is of great importance as such agents may allow time for therapeutic measures to be accomplished which could restore cerebral perfusion. This issue is of particular pertinence in the treatment of complex cerebrovascular diseases when local (or global) cerebral blood flow must be interrupted during vascular reconstruction. Thiopental achieved great popularity once protective properties were demonstrated experimentally. Unfortunately, serious cardiovascular depression associated with high-dose barbiturates as well as prolonged duration of action may decrease collateral flow and limit their utility. Etomidate is a nonbarbiturate carboxylated imidazole which is capable of similar cerebral metabolic suppression without significant cardiac side effects. Accumulating experimental evidence supports the protective properties of this drug and suggests that it may be valuable clinically for this purpose. Significant adrenal suppression is a major toxic effect that must be treated if large doses or protracted administration is planned.

UR - http://www.scopus.com/inward/record.url?scp=0027567529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027567529&partnerID=8YFLogxK

M3 - Article

C2 - 8452760

AN - SCOPUS:0027567529

VL - 5

SP - 17

EP - 32

JO - Cerebrovascular and Brain Metabolism Reviews

JF - Cerebrovascular and Brain Metabolism Reviews

SN - 1040-8827

IS - 1

ER -